Мақола

Comparing renal denervation versus pharmacological optimization in uncontrolled hypertension

Olimova GulkhayoDepartment of Nephrology and Hemodialysis, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, UzbekistanSharifov AkmalBukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, UzbekistanРозихон ХакимоваCandidate of Medical Sciences, Department of Phthisiology and pulmonology, Andijan State Medical Institute, UzbekistanGavkhar JalolovaPhD, Department of Obstetrics and gynecology, reproductology, Tashkent state medical university, Tashkent, UzbekistanBazarova ZarinaAssistant (Med.), Obstetrics and gynecology, Samarkand State Medical University, Samarkand, UzbekistanBobojonova NilufarDepartment of Epidemiology and infectious disease Treatment, nursing, Fergana Medical Institute of Public Health, Fergana, UzbekistanKhamroeva Lola- PhD, Department of Anatomy and Clinical Anatomy (OSTA), Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan;Eshbekov MurodPhD, Director of the Samarkand Regional Branch, Republican Emergency Medical Center Specialist in Allergology and Immunology, Samarkand, UzbekistanMurtazaeva KhadichaTermez branch of Tashkent State Medical University, Termez, Uzbekistan

Zenodo (CERN European Organization for Nuclear Research)repository2026en

ABI

Аннотация

Uncontrolled hypertension persists as a major cardiovascular threat in Uzbekistan, where resistant cases challenge standard pharmacological approaches. This prospective randomized controlled trial, conducted at the Republican Specialized Scientific-Practical Medical Center of Cardiology in Tashkent from January 2024 to December 2025, compared renal denervation (RDN) versus pharmacological optimization (PO) in 120 adults with office SBP ≥160 mmHg despite triple therapy. Patients were randomized 1:1; RDN used Symplicity Spyral™ ablation, while PO involved up-titration to five agents. Primary endpoint was 12-month change in 24-hour ambulatory SBP. Baseline traits were balanced (mean age 59 years, SBP 172 mmHg). RDN yielded a -30.5 mmHg SBP drop versus -16.6 mmHg for PO (between-group difference -13.2 mmHg, 95% CI -18.1 to -8.3, P<0.001), with superior responder rates (82% vs. 52%, P<0.001) and control (<130/80 mmHg: 58% vs. 27%). Drug burden fell to 2.8 versus 4.6 agents (P<0.001), with quality-of-life gains (+0.12 vs. +0.05 EQ-5D, P=0.002). Safety was comparable (serious AEs: 9% vs. 13%). RDN shows marked efficacy and simplification in this real-world Uzbek cohort, supporting its role in resistant hypertension management amid local constraints. These findings urge guideline updates for device therapies in Central Asia.

Ҳали таржима қилинмаган

Мавзулар

Blood Pressure and Hypertension Studies Heart rate and cardiovascular health Chronic Kidney Disease and Diabetes

Идентификаторлар

DOI: 10.5281/zenodo.20430571

Иқтибослар ва манбалар

0 та иқтибос0 та фойдаланилган манба

Кўрсаткичлар — AkademScholar